Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant
Intelligent Bio Solutions (INBS) announced the anticipated receipt of its sixth U.S. patent, strengthening protection for its lateral flow technology used in the Intelligent Fingerprinting Drug Testing Solution. The patent will safeguard the company's unique fingerprint sweat-based drug screening technology.
The expected patent grant comes as INBS advances its U.S. market entry strategy planned for 2025. The company's proprietary non-invasive drug testing technology addresses growing demand for workplace safety and compliance solutions. INBS has recently submitted an FDA 510(k) application and aims to expand its global market presence with this innovative sweat-based approach to drug screening.
Intelligent Bio Solutions (INBS) ha annunciato il previsto ricevimento del suo sesto brevetto statunitense, rafforzando la protezione per la sua tecnologia a flusso laterale utilizzata nella Soluzione di Test per Droghe con Impronte Digitali Intelligenti. Il brevetto proteggerà la tecnologia unica dell'azienda basata sul sudore delle impronte digitali per lo screening delle droghe.
Il rilascio del brevetto previsto arriva mentre INBS avanza nella sua strategia di ingresso nel mercato statunitense pianificata per il 2025. La tecnologia di test per droghe non invasiva proprietaria dell'azienda risponde alla crescente domanda di soluzioni per la sicurezza e la conformità sul posto di lavoro. INBS ha recentemente presentato una domanda FDA 510(k) e mira ad espandere la sua presenza globale nel mercato con questo approccio innovativo allo screening delle droghe basato sul sudore.
Intelligent Bio Solutions (INBS) anunció la esperada recepción de su sexta patente en EE.UU., fortaleciendo la protección de su tecnología de flujo lateral utilizada en la Solución de Pruebas de Drogas con Huellas Dactilares Inteligentes. La patente protegerá la única tecnología de detección de drogas basada en el sudor de huellas dactilares de la empresa.
La concesión de la patente esperada se produce mientras INBS avanza en su estrategia de entrada al mercado estadounidense, planeada para 2025. La tecnología de pruebas de drogas no invasiva y patentada de la empresa aborda la creciente demanda de soluciones para la seguridad y el cumplimiento en el lugar de trabajo. INBS ha presentado recientemente una solicitud FDA 510(k) y busca expandir su presencia en el mercado global con este enfoque innovador de detección de drogas basado en el sudor.
Intelligent Bio Solutions (INBS)는 미국에서 여섯 번째 특허를 받을 예정이라고 발표하며, Intelligent Fingerprinting Drug Testing Solution에서 사용되는 측면 흐름 기술에 대한 보호를 강화했습니다. 이 특허는 회사의 독특한 지문 땀 기반 약물 선별 기술을 보호합니다.
예상되는 특허 승인은 INBS가 2025년을 계획하고 있는 미국 시장 진입 전략을 추진하는 가운데 이루어집니다. 회사의 독점적인 비침습적 약물 테스트 기술은 직장 안전 및 규정 준수 솔루션에 대한 증가하는 수요를 충족합니다. INBS는 최근 FDA 510(k) 신청서를 제출했으며, 이 혁신적인 땀 기반 약물 선별 접근 방식으로 글로벌 시장 입지를 확장할 계획입니다.
Intelligent Bio Solutions (INBS) a annoncé la réception anticipée de son sixième brevet américain, renforçant la protection de sa technologie à flux latéral utilisée dans la Solution de Test de Drogues par Empreintes Digitales Intelligentes. Ce brevet protégera la technologie unique de dépistage des drogues basée sur la sueur des empreintes digitales de l'entreprise.
La délivrance du brevet prévue intervient alors qu'INBS avance dans sa stratégie d'entrée sur le marché américain prévue pour 2025. La technologie de test de drogues non invasive et propriétaire de l'entreprise répond à la demande croissante de solutions de sécurité et de conformité en milieu de travail. INBS a récemment soumis une demande FDA 510(k) et vise à étendre sa présence sur le marché mondial avec cette approche innovante de dépistage des drogues basée sur la sueur.
Intelligent Bio Solutions (INBS) hat den erwarteten Erhalt seines sechsten US-Patents bekannt gegeben, das den Schutz seiner Lateralen Fluss-Technologie stärkt, die in der Intelligent Fingerprinting Drug Testing Solution verwendet wird. Das Patent wird die einzigartige, auf Fingerabdruckschweiß basierende Drogen-Screening-Technologie des Unternehmens schützen.
Die erwartete Patenterteilung erfolgt, während INBS seine Strategie für den Eintritt in den US-Markt plant, die für 2025 vorgesehen ist. Die proprietäre, nicht-invasive Drogen-Testtechnologie des Unternehmens reagiert auf die wachsende Nachfrage nach Sicherheits- und Compliance-Lösungen am Arbeitsplatz. INBS hat kürzlich einen FDA 510(k)-Antrag eingereicht und zielt darauf ab, seine globale Marktpräsenz mit diesem innovativen, schweißbasierten Ansatz für das Drogen-Screening auszubauen.
- Expected sixth U.S. patent strengthens IP protection
- FDA 510(k) submission completed
- Planned U.S. market entry in 2025
- Patent grant not yet officially received
- U.S. market revenue generation still pending until 2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it expects to receive its sixth patent in the United States, which will strengthen the protection of the lateral flow technology core to its Intelligent Fingerprinting Drug Testing Solution.
This expected patent will enhance INBS’ existing intellectual property portfolio, which safeguards its unique fingerprint sweat-based drug screening technology. The anticipated grant will help ensure that the Company’s lateral flow technology remains protected as it advances its U.S. market entry strategy.
“Protecting our proprietary technology is critical as we plan to scale our footprint in the U.S. drug screening market,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “This expected patent will further strengthen our portfolio and secure the innovation behind our drug testing solution.”
As more and more industries prioritise workplace safety and compliance, the demand for smart, efficient, and non-invasive drug testing solutions continues to rise. INBS’ proprietary technology is designed to meet these evolving needs, providing a non-invasive alternative to traditional drug screening methods. With its innovative sweat-based approach, recent FDA 510(k) submission, and strategic plans to enter the U.S. market in 2025, INBS is well-positioned to drive industry transformation and expand its global market presence.
Further details on the patent grant will be announced upon official issuance of the patent.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
When is Intelligent Bio Solutions (INBS) planning to enter the U.S. market?
What is the status of INBS's FDA application for their drug testing technology?
How many U.S. patents will INBS hold after this new patent grant?
What type of technology does INBS's drug testing solution use?
